| Drug | Class | Pharmacologic target | Myelosuppressive effect | US pregnancy category | Indications | Notable adverse effects |
| Methotrexate[3] | Antineoplastic & immunosuppressant | Mammalian DHFR | +++ | X | Malignancies (esp. haematologic malignancies and osteosarcoma), ectopic pregnancy and autoimmune conditions (esp. rheumatoid arthritis, psoriasis, Granulomatosis with polyangiitis, Goodpasture syndrome, etc.) | Kidney or liver failure, Stevens–Johnson syndrome, toxic epidermal necrolysis, infection, aplastic anaemia, opportunistic infections and GI effects. |
| Pemetrexed[4] | Antineoplastic | Mammalian DHFR, TS, GARFT | +++ | D | Non-small cell lung carcinoma & mesothelioma | Nausea, vomiting, dyspnoea, constipation, chest pain, diarrhoea, weight loss, stomatitis, rash, fever, peripheral neuropathy, dehydration, kidney failure, Stevens–Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. |
| Proguanil[5] | Antimalarial | Protozoal DHFR | ± | C | Malaria, prevention and treatment | Abdominal pain, headaches, increased LFTs, myalgia, nausea, opportunistic infections, diarrhoea, vomiting, etc. Less commonly Stevens–Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, liver failure, anaphylaxis, etc. |
| Pyrimethamine[6] | Antiprotozoal | Protozoal DHFR | ± | C | Malaria, toxoplasmosis and pneumocystis jiroveci pneumonia. | Stevens–Johnson syndrome, toxic epidermal necrolysis, agranulocytosis and aplastic anaemia. |
| Trimethoprim[7] | Broad-spectrum antimicrobial | Microbial DHFR | ± | C | Numerous (especially when in combination with the sulfonamide, sulfamethoxazole); treatment & prophylaxis for pneumocystis jiroveci pneumonia, malaria and toxoplasmosis. Treatment of melioidosis, shigellosis, listeria, urinary tract infections, acute infectious exacerbations of chronic bronchitis, infection prophylaxis in HIV-positive individuals, cyclospora protozoa, etc. | Stevens–Johnson syndrome, toxic epidermal necrolysis, agranulocytosis and aplastic anaemia. |